Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte (INCY) PT Raised to $87 at RBC Capital
July 30, 2019 3:18 PM EDTRBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $87.00 (from $85.00) while maintaining a Sector Perform rating.
... MoreIncyte (INCY) Tops Q2 EPS by 27c, Raises Guidance
July 30, 2019 7:06 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of $0.75, $0.27 better than the analyst estimate of $0.48. Revenue for the quarter came in at $510 million versus the consensus estimate of $496.4 million.
Guidance:
The... More
